Biomx

Biomx EBITDA Margin

The EBITDA Margin of Biomx (PHGE) as of Nov 4, 2026 is 7,535.85 %. In the previous year, EBITDA Margin was 18,062.69 % — a change of -58.28% (lower).

EBITDA Margin

7,535.85 %

YoY

-58.28%

Last updated:

EBITDA Margin of Biomx is 2023 7,535.85 % . EBITDA Margin of Biomx was 2022 18,062.69 % . It decreases by -58.28% lower compared to the previous year.

The Biomx EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2022
18,062.69 USD
Jan 1, 2023
7,535.85 USD
The Biomx EBITDA Margin history
YEAREBITDA MarginYoY
7,535.85 %-58.28%
18,062.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Biomx Stock analysis

What does Biomx do? BiomX Ltd develops bacteriophage-based therapies targeting dysbiosis-related diseases, focusing on natural and engineered phage solutions. The company's pipeline includes BX001 for acne-prone skin, BX002 for IBD bacterial targets, and BX003 for Klebsiella pneumoniae strains. BiomX discovers and validates bacterial targets to customize phage compositions, aiming to treat conditions like inflammatory bowel disease, primary sclerosing cholangitis, and cancer through targeted bacterial destruction. The firm creates therapies for skin appearance issues and chronic diseases, with BX001 addressing acne, BX002 targeting IBD onset bacteria, and BX003 focusing on specific Klebsiella pneumoniae strains. BiomX's approach involves developing both natural and engineered phage cocktails tailored to bacterial targets, ensuring precise treatment for microbiome-related conditions without naming specific buyers or segments. BiomX Ltd's revenue model relies on the development and commercialization of its phage therapy pipeline. The company's products BX001, BX002, and BX003 are designed to treat specific bacterial-related conditions, with BX001 targeting skin appearance, BX002 for IBD, and BX003 for Klebsiella pneumoniae, all developed through customized phage compositions against validated bacterial targets. Biomx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomx stock

EBITDA Margin of Biomx is 7,535.85 % in 2023.

EBITDA Margin of Biomx changed from 18,062.69 % to 7,535.85 %, representing a -58.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Biomx since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Biomx with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Biomx

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Biomx